The company's second-quarter report showed the continuing impact of shrinking generic drug sales on the country's largest pharmacy chains.
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
The drugmaker says "there is no alternative" to its restructuring plan amid pricing pressure on its core generics business.
The company's revenue rose 13% but the core generics business experienced "accelerated price erosion and decreased volume."
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
But the drugstore chain's same store-sales fell short of estimates in part due to the introduction of low-margin generic drugs.
A collection of CFO.com articles and stories published on July 27, 2015.
